Hepatocellular carcinoma (HCC), the most common form of liver cancer, continues to pose a significant global health challenge ...

Systemic therapy represents the standard of care treatment for patients with advanced hepatocellular carcinoma (HCC). Given ...

LIVER CANCER, the third leading cause of cancer-related deaths globally, is primarily attributed to hepatocellular carcinoma ...

The U.S. FDA granted breakthrough device designation to Mursla Bio Ltd.'s Evoliver. The biopsy blood test uses extracellular vesicles to survey hepatocellular carcinoma in high-risk cirrhotic patients ...

A new study reveals how a critical imbalance in bile acids—the substances made by the liver that help digest fats—can trigger ...

The fig summarizes the main treatment strategies for HCC. Hepatocellular carcinoma (HCC) is the most prevalent form of liver cancer, accounting for the majority of primary liver cancer cases.

The clinical trial will include nearly 150 patients with advanced hepatocellular carcinoma that expresses glypican-3.

as a first-line treatment for adults with unresectable or metastatic hepatocellular carcinoma (HCC), a primary liver cancer. The approval is anchored in the outcomes from the open-label randomised ...

There are several different types of primary liver cancer. The most common type is hepatocellular carcinoma, which begins in the main type of liver cell (hepatocyte). Other types of liver cancer, like ...

The company said that its test could overcome sensitivity issues with ultrasound and serum alpha-fetoprotein assays that are used to monitor at-risk patients.

Hepatocellular carcinoma (HCC) represents the most prevalent malignancy in Egypt and globally. However, non-invasive diagnostic/prognostic biomarkers for early detection of HCC are still lacking.